NHMRC to Fund Major Phase 2 Clinical Trial of Cynata’s Cymerus MSCs in Patients with Osteoarthritis

Cynata Therapeutics (ASX:CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that the Australian National Health...

Genetics Outlook 2019: CRISPR Technology Advances

With 2018 coming to a close, here's a look at the biggest genetics trends of the year and what's in...

Cynata CYP-001 Stem Cell Therapy Meets All Safety and Efficacy Endpoints in Phase 1 Trial in GvHD

Australian stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) is pleased to announce that CYP-001, its lead Cymerus...

Cynata Therapeutics Completes Patent Application to Cover Cymerus Stem Cell Technology

Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) announced that it has completed the filing of a...

Cynata Therapeutics Receives Orphan Drug Designation from FDA

The orphan drug designation is a unique mission that incentivizes companies to develop treatments for the rare disease market.

FDA Grants Orphan Drug Designation to Cynata’s Lead Cymerus MSC Product, CYP-001

Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the United States Food...

Excellent Cohort A Data From Final Primary Evaluation Period in Cynata GvHD Phase 1 Clinical Trial

Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the Primary Evaluation Period...